Company intelligence / Profile preview

metaLead Therapeutics

Zurich, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

metaLead's preclinical lead peptide candidates show superior efficacy and selectivity compared to the standard of care, with compelling data in mice demonstrating strong metal expulsion even at lower oral doses, while maintaining essential metals and limiting off-target effects

Therapeutic areas: NeurologyRare DiseasesMetabolic DisordersOther
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

BaseLaunchUZH Life Sciences FundBioInnovation InstituteKickFundVenture KickInnosuisse

Beyond the preview

Go deeper on metaLead Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metaLead Therapeutics.

Explore the full profile